title: Galanin and NPY, two peptides with multiple putative roles in the nervous system.
abstract: In the present brief overview we summarize results from several studies focusing on two neuropeptides, galanin and neuropeptide Y (NPY) in discrete neuronal systems, where they coexist with classic transmitters. On the basis of studies in different animal models we propose that these peptides may be involved in regulation of certain CNS functions and that drugs acting on their receptors may be of use in new therapeutic strategies. At the spinal level galanin and NPY are regulated in DRG neurons by nerve injury and in dorsal horn neurons by inflammation. It is possible that this leads to attenuation of pain sensitivity. Moreover, both peptides may exert trophic effects, for example to enhance regeneration. In the hypothalamic arcuate nucleus NPY and its receptors are part of the feeding circuitry, and we suggest that derangement of these NPY neurons may at least in part underlay the lethal phenotype of anorectic mice, which die 22 days postnatally after showing decreased food intake and growth retardation. Expression of NPY and NPY receptors is changed in the hippocampus of mice comparatively early after prion inoculation, indicating that this peptide system is affected in this spongiform degenerative disease in a region of importance for learning and memory. Finally, galanin is co-localized with classic monoamine transmitters in two central systems, the dorsal raphe serotonin neurons and the locus coeruleus noradrenergic neurons. In both cases galanin causes hyperpolarization (at high concentrations) and prolongs monoamine-induced outward currents (at low concentrations), thus modulating activity in two systems of importance for many brain functions including mood regulation. It may therefore be interesting to analyse to what extent drugs affecting galaninergic transmission also may be efficient in the treatment of, for example, depression.
authors.affiliation: Dept. of Neuroscience, Karolinska Institutet, Stockholm, Sweden. Tomas.Hokfelt@neuro.ki.se
authors.forename: T
authors.initials: T
authors.lastname: Hökfelt
authors.forename: C
authors.initials: C
authors.lastname: Broberger
authors.forename: M
authors.initials: M
authors.lastname: Diez
authors.forename: Z Q
authors.initials: ZQ
authors.lastname: Xu
authors.forename: T
authors.initials: T
authors.lastname: Shi
authors.forename: J
authors.initials: J
authors.lastname: Kopp
authors.forename: X
authors.initials: X
authors.lastname: Zhang
authors.forename: K
authors.initials: K
authors.lastname: Holmberg
authors.forename: M
authors.initials: M
authors.lastname: Landry
authors.forename: J
authors.initials: J
authors.lastname: Koistinaho
mesh_terms: D000818:Animals; D000928:Antidepressive Agents; D004435:Eating; D019004:Galanin / Q000502:physiology*; D006801:Humans; D009424:Nervous System Physiological Phenomena; D009478:Neuropeptide Y / Q000502:physiology*; D010146:Pain; D017096:Prion Diseases
chemical_list: D000928:Antidepressive Agents; D009478:Neuropeptide Y; D019004:Galanin